FindMyKOL

Gregory Kane, MD

Basic profile

Thomas Jefferson University

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionPhiladelphia, PA · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Gregory Kane is a Respiratory physician affiliated with Thomas Jefferson University. OpenAlex indexes 181 publications with 3,074 citations (h-index 27).

Overview

Scholarship

indexed output and impact (OpenAlex)
181publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

3,074citations

Citations across these publications.

27h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
13companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • GlaxoSmithKline, LLC.
    Program year20253 payments
    $61
  • GlaxoSmithKline, LLC.
    Program year20245 payments
    $99
  • Genentech USA, Inc.
    Program year20242 payments
    $36
All 20 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    58.5%
    Corticosteroid29.5%
    Breo Ellipta34%Trelegy Ellipta18%Fluticasone Propionate17%Symbicort10%Arnuity Ellipta6%Flovent Diskus6%Pulmicort Flexhaler3%Qvar Redihaler3%Breztri Aerosphere3%
    Part D<11 patients
    Leukotriene Receptor Antagonist12.9%
    Montelukast Sodium100%
    Part D≥50 patients

    + 5 more classes in this area

  • Anti-infectives

    16%
    Macrolide Antimicrobial7.8%
    Azithromycin100%
    Part D≥62 patients
    Penicillins with extended spectrum3%
    Amoxicillin-Clavulanate Potass75%Amoxicillin26%
    Part D<11 patients

    + 5 more classes in this area

  • Metabolism & gastrointestinal

    10%
    Corticosteroid6.7%
    Prednisone100%
    Part D≥49 patients
    Proton pump inhibitor2.6%
    Omeprazole61%Pantoprazole Sodium39%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)84.1% facility · 15.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”